Study M1137
Study name | Cristiano C 2022 |
Title | Oral sodium butyrate supplementation ameliorates paclitaxel-induced behavioral and intestinal dysfunction |
Overall design | The aim of this study was to investigate the effects of preventive administration of sodium butyrate in mice treated with one cycle of paclitaxel on gut function and microbiota composition. CD1 mice were divided into the following 4 groups (n = 8 in each group): (1) control group, (2) sodium butyrate group, (3) paclitaxel group, and (4) paclitaxel + sodium butyrate group. Sodium butyrate was given orally for 44 days in daily drinking water. After 30 days, mice then received paclitaxel or vehicle were injected intraperitoneally every other day for a week (days 1, 3, 5, and 7). Seven days after the last injection, mice were subjected to behavioral tests. The treatment with sodium butyrate ameliorated depressive- and anxiety-like behaviors induced by paclitaxel in mice. Levels of short-chain fatty acids were determined using GC-MS (n=5 for each group). |
Study Type | Type1; Type2; Type3; |
Data available | Unavailable |
Organism | Mouse; CD1 mouse; |
Categories of depression | Animal model; Other animal model; Other animal model; Healthy individuals; Healthy individuals; Healthy individuals; |
Criteria for depression | Forced swimming test, tail suspension test |
Sample size | 20 |
Tissue | Peripheral; Faece; Faece; |
Platform | MS-based; GC-MS: not reported; |
PMID | |
DOI | |
Citation | Cristiano C, Cuozzo M, Coretti L, et al. Oral sodium butyrate supplementation ameliorates paclitaxel-induced behavioral and intestinal dysfunction. Biomed Pharmacother. 2022 Sep;153:113528. |
Metabolite |
